6533b861fe1ef96bd12c4e72

RESEARCH PRODUCT

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

Pablo GargalloVictoria CastelJaime Font De MoraDavid HervásLuis SendraVanessa SeguraMiguel A. SanzPablo BerlangaAdela CañeteGladys OliveraSalvador F. AliñoSalvador F. AliñoMaría José HerreroYania Yáñez

subject

Oncologymedicine.medical_specialtySNPSingle-nucleotide polymorphismLogistic regressionsurvivalCalcitriol receptorArticleCatalysislcsh:ChemistryInorganic ChemistryneuroblastomaInternal medicineNeuroblastomamedicineSNPPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopypharmacogeneticsbiologybusiness.industryOrganic ChemistrytoxicityGeneral Medicinemedicine.diseaseComputer Science Applicationslcsh:Biology (General)lcsh:QD1-999Methylenetetrahydrofolate reductaseCohortbiology.proteinbusinessPharmacogenetics

description

Single nucleotide polymorphisms (SNPs) in Pharmacogenetics can play an important role in the outcomes of the chemotherapy treatment in Neuroblastoma, helping doctors maximize efficacy and minimize toxicity. Employing AgenaBioscience MassArray, 96 SNPs were genotyped in 95 patients looking for associations of SNP with response to induction therapy (RIT) and grade 3&ndash

https://doi.org/10.3390/ijms21082714